Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development (Q31148686)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

14 August 2017

Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development (English)

1 reference

Europe PubMed Central

14 August 2017

0 references

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

K Kuester

1

1 reference

Europe PubMed Central

14 August 2017

A Kovar

2

1 reference

Europe PubMed Central

14 August 2017

C Lüpfert

3

1 reference

Europe PubMed Central

14 August 2017

B Brockhaus

4

1 reference

Europe PubMed Central

14 August 2017

C Kloft

5

1 reference

Europe PubMed Central

14 August 2017

language of work or name

0 references

publication date

4 March 2008

1 reference

Europe PubMed Central

14 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

14 August 2017

98

1 reference

Europe PubMed Central

14 August 2017

5

1 reference

Europe PubMed Central

14 August 2017

900-906

1 reference

Europe PubMed Central

14 August 2017

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

Pharmacokinetics of intravenous immunoglobulin: a systematic review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

Overview of monoclonal antibodies in cancer therapy: present and promise

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

Epidermal growth factor receptor inhibition strategies in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

Anticancer antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

Increasing the serum persistence of an IgG fragment by random mutagenesis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

Recombinant human betacellulin. Molecular structure, biological activities, and receptor interaction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

The importance of modeling interoccasion variability in population pharmacokinetic analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

Metabolic properties of IgG subclasses in man

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

Humanization of a mouse monoclonal antibody by CDR–grafting: the importance of framework residues on loop conformation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266843

14 July 2018

Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604265

21 January 2018

Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604265

21 January 2018

Akaike's information criterion in generalized estimating equations.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604265

21 January 2018

A Theoretical Model of γ-Globulin Catabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604265

21 January 2018

Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung

1 reference

https://pubmed.ncbi.nlm.nih.gov/18319714

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18319714

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM

1 reference

https://pubmed.ncbi.nlm.nih.gov/18319714

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18319714

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18319714

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)

1 reference

https://pubmed.ncbi.nlm.nih.gov/18319714

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18319714

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18319714

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6604265

1 reference

Europe PubMed Central

14 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31148686&oldid=2175446341"